In the largest healthcare fraud settlement in U.S. history, pharmaceutical giant GlaxoSmithKline has agreed to pay $3 billion to settle allegations that it engaged in various illegal drug marketing and pricing tactics.
GSK has agreed to plead guilty to a three-count criminal information, which includes two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about Avandia to the Food and Drug Administration.
Under that plea agreement, GSK will pay $1 billion, including a criminal fine of roughly $957 million and forfeiture of $43 million. The pharmaceutical company will also pay $2 billion to resolve civil liabilities with the government and states under the False Claims Act. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK's U.S. president and board of directors.
New York Payor, Medical Group Settle Charges of Improper Billing
Abbott to Pay $1.5B Settlement for Off-Label Marketing of Depakote
GSK has agreed to plead guilty to a three-count criminal information, which includes two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about Avandia to the Food and Drug Administration.
Under that plea agreement, GSK will pay $1 billion, including a criminal fine of roughly $957 million and forfeiture of $43 million. The pharmaceutical company will also pay $2 billion to resolve civil liabilities with the government and states under the False Claims Act. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK's U.S. president and board of directors.
More Articles on Pharmaceutical Fraud:
OIG Seeks Input to Revise Self-Disclosure Protocol for Healthcare ProvidersNew York Payor, Medical Group Settle Charges of Improper Billing
Abbott to Pay $1.5B Settlement for Off-Label Marketing of Depakote